Accessible Search Form           Advanced Search

HHS logo

For Immediate Release: August 1, 2006

NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
Ask for press officer on duty

For Immediate Release: August 1, 2006

  • PRINT  |  SHARE

Media Availability: New Results Show That Some Severe Emphysema Patients Continue to Benefit from Surgery

The latest results from the landmark National Emphysema Treatment Trial (NETT) confirm and extend earlier findings that selected patients with advanced emphysema predominately in the upper area of the lung may benefit from surgery and the benefits are still apparent with two more years of follow-up. The newly published findings from the largest study of bilateral lung volume reduction surgery (LVRS) to treat severe emphysema also confirm that patients with upper-lobe emphysema and poor exercise capacity before surgery are more likely to have improved survival compared to similar patients treated with medical therapy without surgery. Surgery might also provide some symptom relief in patients with emphysema in the upper lung area but who had good exercise capacity prior to surgery; however, survival rates did not improve in this group.

NETT researchers describe the effects of LVRS after following 1218 patients for an average of 4.3 years, two years longer than the primary results reported in 2003. The earlier findings led to Medicare coverage of LVRS for patients meeting criteria based on the study results. NETT began in 1996 as a cooperative effort between the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and the Centers for Medicare & Medicaid Services. Both are agencies of the U.S. Department of Health and Human Services.

"Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema" is published in the August issue of the Annals of Thoracic Surgery.

Gail Weinmann, M.D., director of the NHLBI Airway Biology and Disease Program, is available to comment on the study's findings.

To schedule interviews, contact the NHLBI Communications Office at 301-496-4236.


Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at: www.nhlbi.nih.gov.

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

For the Media

NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
Ask for press officer on duty

Related Health Topics

Clinical Trials

COPD